We demonstrated that monotherapy of three different lines of BRAFmut and KRASmut patient-derived colorectal cancer cells with a MEK inhibitor led to resistance due to compensatory signaling and gain of stemness, consistent with our previous studies using cell lines [9, 12], and suggesting these mechanisms underlie resistance to MEK inhibition [35, 36]. Here, MAP2K7 is linked to colorectal cancer.